ZVRA Q2 2024 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-47.5% YoY

Gross Profit

$876,00019.7% margin

Operating Income

-$24M-534.8% margin

Net Income

-$20M-447.9% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+29.9%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$144M

Total Liabilities

$112M

Stockholders' Equity

$32M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$8M	-47.5%
Gross Profit	$876,000	$8M	-88.8%
Operating Income	-$24M	-$6M	-280.6%
Net Income	-$20M	-$3M	-674.4%

Revenue Segments

License

$1M100%